Acute Urticaria: IgE-Mediated and Non-IgE-Mediated Pathways with Evidence-Based Management

Definition and Overview

Acute urticaria is a cutaneous reaction characterized by rapid onset of pruritic wheals (erythematous, edematous plaques) and/or angioedema (deeper dermal/mucosal swelling) lasting <6 weeks. Unlike chronic urticaria which persists >6 weeks with unclear etiology in 90% of cases, acute urticaria typically has identifiable triggers and resolves spontaneously. Acute urticaria affects 10-20% of the population at least once in their lifetime, making it extremely common. Approximately 30% of acute urticaria episodes are allergic (IgE-mediated Type I hypersensitivity), while 70% are non-allergic (triggered by physical stimuli, medications, food additives, or idiopathic triggers). Acute urticaria is generally benign and prognosis is excellent, but angioedema involving the airway (anaphylaxis) can be life-threatening and requires immediate emergency management with epinephrine.

Epidemiology

Acute urticaria affects 10-20% of the population at some point in their lifetime. Approximately 1-3% of population experiences acute urticaria at any given time. Peak incidence is 20-40 years, with no significant gender difference overall (though some subtypes show female predominance). Seasonal variation exists for allergen-related urticaria (spring/summer for pollens and insects). Geographic variation reflects local allergens and triggers. Atopic individuals (history of allergies, asthma, atopic dermatitis) have 2-3 fold increased risk of allergen-related urticaria. The overall prevalence of food allergy-related acute urticaria is 2-3% in the general population but higher in children (3-5%).

Pathophysiology

IgE-mediated (allergic) acute urticaria (30% of cases): Occurs via Type I hypersensitivity mechanism. Allergen-specific IgE binds to high-affinity IgE receptors on mast cell and basophil surfaces. Upon re-exposure, cross-linking of IgE receptors by allergen triggers rapid intracellular signaling cascades, opening calcium channels and causing exocytosis of granules containing histamine (50% of granule content), tryptase, leukotrienes (C4, D4, E4), prostaglandins (D2, E2), and cytokines (IL-4, IL-8, TNF-α). Histamine binding to H1 receptors on endothelial cells increases vascular permeability; H2 receptors on smooth muscle cause vasodilation. Leukotriene C4 and platelet-activating factor promote further inflammatory cell recruitment and increase vascular permeability. The result is transudation of fluid into dermis, causing wheal formation (usually resolves within 24-48 hours due to rapid histamine degradation and mast cell resensitization).

Non-allergic acute urticaria (70% of cases): Triggered by physical stimuli (cold water inducing cold urticaria, vibration, pressure, delayed pressure urticaria), medications (NSAIDs, ACE inhibitors via bradykinin pathways), food additives (histamine, sulfites, tartrazine), or direct mast cell degranulation. Non-allergic mechanisms activate mast cells without IgE involvement, often through complement activation, direct mast cell triggers, or other pathways. Medications like ASA and NSAIDs inhibit prostaglandin synthesis, shifting balance toward leukotriene production, amplifying inflammatory response.

Common Triggers and Etiologies

IgE-mediated (allergic) triggers:

• Foods: Peanuts, tree nuts, shellfish, fish, eggs, milk, soy (account for 90% of food allergy-related urticaria); reaction typically within 30 minutes to 2 hours
• Medications: Beta-lactam antibiotics (penicillins, cephalosporins), sulfonamides, NSAIDs (ASA, ibuprofen), ACE inhibitors, radiocontrast media
• Insect stings: Hymenoptera (bees, wasps, hornets) in 5-15% of sting-exposed population; cross-reactivity between Vespidae species common
• Latex: Natural rubber latex protein-specific IgE; risk highest in healthcare workers and patients with prior latex exposure
• Aeroallergens: Pollen, animal dander (rare as sole trigger for urticaria; usually cause allergic rhinitis)

Non-allergic/non-IgE-mediated triggers:

• Physical stimuli: Cold (cold urticaria), heat, sun exposure (solar urticaria), vibration, pressure (delayed pressure urticaria, developing 4-6 hours after pressure), exercise, sweating
• Medications: NSAIDs (ASA, ibuprofen, naproxen), ACE inhibitors (captopril, lisinopril), opioids (via direct mast cell degranulation)
• Food additives: Histamine-containing foods (aged cheeses, processed meats, fermented foods), tartrazine (yellow dye #5), sulfites (food preservatives), benzoates
• Infections: Viral upper respiratory infections (EBV, CMV, HAV), bacterial infections (Streptococcus, Helicobacter pylori), parasitic infections
• Idiopathic: 30-50% of acute urticaria cases have no identifiable trigger despite investigation

Clinical Presentation

Acute onset: Lesions develop within minutes to 2-4 hours of trigger exposure (IgE-mediated reactions typically within 30 minutes to 2 hours; non-IgE reactions more variable timing).

Wheal morphology:

• Wheals: Pruritic, erythematous, edematous papules or plaques, ranging from 2-10 mm (small wheals) to >1 cm (large wheals); clustered or individual lesions
• Character: Wheals are transient—individual lesions resolve within 24-48 hours (defining feature), though new lesions may continue to appear as long as trigger is present
• Distribution: Symmetric or asymmetric; commonly involve trunk, extremities, and face
• Color: Pale erythematous center with surrounding hyperemic flare (some lesions are completely blanching, others non-blanching)
• Positive Darier sign: Stroking affected skin produces localized wheal formation (helpful diagnostic sign)

Angioedema:

• Character: Deeper dermal/subcutaneous edema causing well-demarcated swelling of face (lips, eyelids, tongue, pharynx), hands, feet, or throat
• Distinguishing features: Angioedema is non-pruritic (unlike wheals), non-pitting, with normal overlying skin, and resolves over hours to days (slower than wheals)
• Location: Commonly periorbital, perioral, lips, ears, hands/feet; pharyngeal/laryngeal angioedema is medical emergency
• Severity: Mild angioedema (localized facial swelling) vs. severe (airway compromise)

Systemic symptoms: Pruritus (mild to severe), burning sensation; fever absent unless concurrent infection; respiratory symptoms only if airway involved; gastrointestinal symptoms (nausea, abdominal pain, diarrhea) in food-induced urticaria

Diagnosis

Clinical diagnosis: Characteristic presentation of transient pruritic wheals (<24-hour individual lesion duration) and/or angioedema is diagnostic. Temporal relationship to suspected trigger is essential. The key distinguishing feature is transience—individual wheals resolve within 24-48 hours; persistence suggests alternative diagnosis.

Skin prick testing: For suspected IgE-mediated allergy, prick test with suspected allergen (food extract, aeroallergen, venom) reproduces wheal at 15-20 minutes if sensitized. Positive test shows wheal ≥3 mm greater than negative control saline. Prick testing is particularly useful for food and venom allergies.

Specific IgE testing: Serum IgE to suspected allergens (CAP-FEIA method) measures allergen-specific IgE levels. Results >0.35 kU/L indicate sensitization; higher levels correlate with clinical symptoms. Safer than skin testing in patients at risk for systemic reactions.

Laboratory testing: Usually not needed for typical acute urticaria. CBC, comprehensive metabolic panel, and C-reactive protein (CRP) are typically normal. Consider testing for infection (viral serology, bacterial cultures) if systemic symptoms prominent or infection suspected as trigger.

Provocation testing: For suspected physical urticaria (cold, heat, exercise), provocation testing under controlled conditions can reproduce symptoms (e.g., cold challenge test with ice cube application for cold urticaria)

Differential Diagnosis

Contact dermatitis: Presents with localized pruritic lesions but duration is longer (days to weeks with individual lesions) and demarcation follows contact pattern (not random distribution). Histology shows lymphocytic infiltrate vs. mast cell predominance in urticaria.

Urticarial vasculitis: Individual lesions persist >48 hours, painful/burning more than pruritic, and may leave bruising or purpura. Systemic symptoms (fever, joint pain) more prominent. Histology shows leukocytoclastic vasculitis.

Mastocytosis: Persistent urticaria with dermographism, flushing, and systemic symptoms (diarrhea, syncope). Serum tryptase elevated. Skin biopsy shows mast cell infiltration.

Treatment

Trigger identification and avoidance: First-line management is identifying and avoiding the trigger. For food-triggered urticaria, strict allergen avoidance is essential. For medication-triggered urticaria, alternative medication from different class should be substituted if possible.

Acute attack management:

• First-generation antihistamines (H1 blockers): Most effective for acute attacks. Cetirizine 10 mg PO, loratadine 10 mg PO, or fexofenadine 180 mg PO provide symptom relief within 30-60 minutes. Diphenhydramine 25-50 mg PO (more sedating) acceptable for acute severe episodes. For severe acute urticaria, consider IV diphenhydramine or hydroxyzine.
• H2 blockers (adjunctive): Cimetidine 300 mg BID or ranitidine (histamine H2 receptors on vascular endothelium contribute to vasodilation); combined H1/H2 blockade may be more effective than H1 blockade alone
• Systemic corticosteroids: Generally not recommended for acute urticaria alone (minimal efficacy for histamine-mediated reactions), but may benefit non-allergic variants or cases with systemic symptoms (prednisone 0.5-1 mg/kg daily for 3-5 days if severe)
• Epinephrine: For anaphylaxis with airway involvement (urticaria + angioedema + respiratory symptoms ± hypotension). Administer IM epinephrine 0.3-0.5 mg (1:1000) immediately. May repeat every 5-15 minutes as needed. IV access, oxygen, and hospitalization required.
• Cool compresses and emollients: Supportive care; avoid hot water, which degranulates mast cells and worsens urticaria

Chronic management (if symptoms persist >6 weeks, transition to chronic urticaria protocol): Second-generation (non-sedating) antihistamines first-line: cetirizine 10 mg daily, loratadine 10 mg daily, or fexofenadine 180 mg daily; dose escalation (up to 4x standard dose) if response inadequate; addition of omalizumab (anti-IgE monoclonal antibody) for refractory cases (effective in allergic urticaria with elevated IgE); cyclosporine for severe refractory cases

Prognosis

Excellent. Most acute urticaria episodes resolve spontaneously within 24-72 hours. With trigger avoidance, resolution occurs in 90% within 1-2 weeks. Even without treatment, urticaria typically resolves within 6 weeks. Recurrence depends on re-exposure to trigger. However, 30% of acute urticaria episodes progress to chronic urticaria (persisting >6 weeks) when trigger is not identified or cannot be avoided. Anaphylactic reactions (urticaria + airway involvement + hypotension) can be life-threatening but are rare in acute food-related urticaria in adults (1-2% of food-allergic individuals progress to anaphylaxis).

Prevention

Trigger identification: Maintaining symptom diary documenting timing of urticaria episodes, suspected triggers (foods eaten, medications, environmental exposures, physical stimuli), and associated symptoms helps identify patterns and triggers.

Allergen avoidance: Once trigger identified, strict avoidance is essential. For food allergies, careful label reading and restaurant communication are critical. For medication-induced urticaria, transition to alternative medication from different drug class.

Medical alert identification: Patients with history of anaphylaxis (urticaria + systemic symptoms) should carry medical alert identification and epinephrine auto-injectors (EpiPen 0.3 mg for patients 15-30 kg, 0.5 mg for >30 kg; prescribed as 2 auto-injectors in case repeat injection needed).

Frequently Asked Questions

How long does acute urticaria last?

Individual wheals resolve within 24-48 hours (this is the defining feature—if wheals persist longer, consider other diagnoses like urticarial vasculitis). However, new wheals may continue appearing as long as the trigger is present. Once the trigger is removed or avoided, new wheal formation stops and existing wheals resolve, typically resulting in complete clearance within 3-7 days. If urticaria persists >6 weeks, it is classified as chronic urticaria with different prognosis and management.

Can I use hydrocortisone cream for urticaria?

Topical corticosteroids provide minimal benefit for acute urticaria since the problem is mast cell degranulation releasing systemic histamine. Systemic (oral) antihistamines are first-line treatment. However, topical corticosteroids can be applied for supportive care to reduce itching and any concurrent skin inflammation, but should not replace systemic antihistamines for treatment.

What's the difference between acute and chronic urticaria?

Duration is the key difference: acute urticaria lasts <6 weeks (usually 3-7 days with trigger avoidance), while chronic urticaria persists >6 weeks. In acute urticaria, a trigger is usually identifiable (food, medication, infection, physical stimulus). In chronic urticaria, 90% of cases have no identifiable trigger despite testing. Management differs: acute urticaria focuses on trigger avoidance and antihistamines; chronic urticaria requires ongoing antihistamine therapy and consideration of escalation therapies if refractory.

Can food allergy urticaria develop at any age?

Yes, though food allergy typically begins in childhood (peanut, tree nut, shellfish, fish allergies often manifest in childhood or early adolescence). However, new-onset food allergy can develop in adulthood from foods previously tolerated. If you develop urticaria after eating a food you've previously eaten without problem, evaluate for new sensitization; cross-reactivity to related foods may develop (oral allergy syndrome from related plant families). Consult an allergist for testing if new food allergy is suspected.

References